title: [Efficiency of oncologic treatments for solid tumours in Spain].
abstract: OBJECTIVE
  To provide estimates of the efficiency for chemotherapy strategies used in Spain.
  
  
  METHODS
  Published reports of the phase-III clinical trials for chemotherapies used for the most prevalent solid tumours in Spain were retrieved. The incremental cost-effectiveness ratio (ICER) was calculated for each strategy compared to the control group in the clinical trial, with the National Health System perspective. The total cost (?, 2012) including only drug cost (exfactory price) was estimated based on the total units of each drug required for administration (no vial wastage), with the dosification and number of cycles specified in the publication for each treatment arm. Effectiveness was measured as month of overall survival (OS) and/or month of progression free survival (PFS).
  
  
  RESULTS
  A total of 40 chemotherapies for 13 different advanced or metastatic tumours were assessed. OS ranged from 5.3 to 33.3 months for the 34 therapies that included the information with hazard ratios (HR) values from 0.49 to 1.15 when compared with its control group. PFS ranged, from 39 therapies with these data, between 1.5 to 12.4 months, with HR from 0.33 to 1.52. ICERs were between ?2,142.57 and ?60,996.37 per each OS month gained, and from ?2,102.54 to ?661,845.27 per PFS month gained.
  
  
  CONCLUSIONS
  The variety and heterogenicity of survival and ICERs results, suggest disparity of criteria in the price and reimbursement process of drugs in Spain. The continuous advances in oncology seem to require economic revaluations of drugs.
authors.forename: I
authors.initials: I
authors.lastname: Oyagüez
authors.forename: C
authors.initials: C
authors.lastname: Frías
authors.forename: M Á
authors.initials: MÁ
authors.lastname: Seguí
authors.forename: M
authors.initials: M
authors.lastname: Gómez-Barrera
authors.forename: M Á
authors.initials: MÁ
authors.lastname: Casado
authors.forename: M
authors.initials: M
authors.lastname: Queralt Gorgas
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000145:classification / Q000191:economics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D016527:Drug Costs / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D016016:Proportional Hazards Models; D013030:Spain / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents